
Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Targeted Search
Clinical Trials Search Results
Query: "TILT[LastUpdatePostDate]SEARCH[Study]AREA[SponsorSearch]Horizon Pharma"
Count: 78
Selected: 0
NCT ID | Title |
---|
NCT01466166 | Observational Study of the Use of Pegloticase (KRYSTEXXA®) in Refractory Chronic Gout | ||
NCT03298867 | Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study | ||
NCT03461211 | Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study | ||
NCT04040894 | Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease | ||
NCT01733316 | Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-Release Capsules (RP103) in Cystinosis | ||
NCT01197378 | Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) | ||
NCT02473445 | A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease | ||
NCT01868997 | Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease | ||
NCT01744782 | Safety/Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cysteamine Treatment Naive Patients With Cystinosis | ||
NCT01270347 | Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients | ||
NCT01180634 | MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis | ||
NCT00840333 | "Safety, Tolerability and Pharmacokinetics of MP-376 Administered for 14 Days to Stable Pediatric (CF) Patients" | ||
NCT00752414 | A Phase 1b Study to Evaluate the Safety and PK of MP-376 in Chronic Obstructive Pulmonary Disease (COPD) Patients | ||
NCT00739648 | A Phase 2 Study of MP-376 to Prevent Acute Exacerbations in Chronic Obstructive Pulmonary Disease (COPD) Patients | ||
NCT00677365 | Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) Patients | ||
NCT00503490 | Safety, Pharmacokinetic and Pharmacodynamic Study of MP-376 in Patients With Cystic Fibrosis | ||
NCT02023866 | Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease | ||
NCT00661141 | Phase IIa Study of Fomepizole for Acetaldehyde Toxicity After Ethanol Exposure in Subjects With Altered Ethanol Metabolism | ||
NCT01000961 | Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis | ||
NCT00872729 | Pilot Study of Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of RP103 Compared to Cystagon® in Patients With Cystinosis | ||
NCT05626751 | An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc) | ||
NCT00986895 | A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control Group | ||
NCT00977600 | A Study of Glyceryl Tri-(4-phenylbutyrate) (GT4P) | ||
NCT02593773 | Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study | ||
NCT02797080 | Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia | ||
NCT02415127 | Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia | ||
NCT01544114 | A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA) | ||
NCT02287610 | A Non-Interventional Study of RAYOS in Adult Patients With Rheumatoid Arthritis | ||
NCT01347073 | Study of the Safety, Pharmacokinetics and Efficacy of HPN-100, in Pediatric Subjects With Urea Cycle Disorders (UCDs) | ||
NCT01135680 | Double-Blind Randomized Crossover Trial to Access Electrocardiogram Effects of HPN-100 | ||
NCT00999167 | A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy | ||
NCT00992459 | Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle Disorders | ||
NCT00947544 | Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children With Urea Cycle Disorders | ||
NCT00947297 | Study of the Safety of HPN (Hyperion)-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD) | ||
NCT00551200 | Dose-Escalation Safety Study of HPN-100 to Treat Urea Cycle Disorders | ||
NCT00597909 | Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy | ||
NCT01563185 | Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis | ||
NCT00984815 | Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment | ||
NCT00650078 | Study to Assess the Safety and Efficacy of Modified-Release Prednisone (Lodotra®) Therapy in Patients With Active Rheumatoid Arthritis | ||
NCT00613106 | Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216) | ||
NCT00450658 | Efficacy and Safety Study of HZT-501 in Reducing the Risk of Ibuprofen-associated Ulcers | ||
NCT00450216 | Efficacy and Safety Study of HZT-501 in Subjects Requiring Nonsteroidal Anti-Inflammatory Drug (NSAID) Treatment | ||
NCT00686335 | A New Modified-release Tablet Formulation of Prednisone (Lodotra®) in Patients With Nocturnal Asthma | ||
NCT03162341 | Study of the Correlation Between UltraSonography and Dual-Energy Computed Tomography Assessment of Urate Deposit | ||
NCT04628338 | IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation | ||
NCT02927158 | Exome and Genome Analysis to Elucidate Genetic Etiologies and Population Characteristics in the Plain Community | ||
NCT03112590 | Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer | ||
NCT04125459 | Assessing the Role of the NLRP3 Inflammasome in Intercritical Gout | ||
NCT02584608 | Use of ACTIMMUNE in Patients With ADO2 | ||
NCT02614456 | Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors |